GlassScriptPhysician profile
Marcella Wheeler
NPI 1487600227
$1,655.05
in general payments reported to CMS, 2019-2025
18 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $18.87 · 2023: $434 · 2024: $547 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $399.68 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $352.26 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $202.51 | 2022-2025 | Jardiance, Mounjaro |
| Abbvie INC. | $167.13 | 2021-2025 | |
| Novo Nordisk INC | $77.25 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $75.47 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $72.05 | 2023-2024 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.95 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $42.40 | 2023 | Quviviq |
| Dexcom, INC. | $39.35 | 2024 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $33.12 | 2025 | Rezdiffra |
| Pfizer INC. | $26.15 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.44 | 2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $21.83 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.52 | 2023 | Uptravi, Opsumit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $18.91 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astellas Pharma US INC | $14.34 | 2025 | Veozah |
| Philips North America LLC | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.